Clinical trial · Interventional
Candin Safety & Efficacy Study for the Treatment of Warts
Study of the Safety and Effectiveness of Candin for the Treatment of Common Warts
NCT01757392CI-TRIAL-00049845completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Human Papilloma Virus | — | UNRESOLVED | — |
| Warts | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Candida albicans Skin Test Antigen | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Candin® 0.3 mL
- description
- Monthly intralesional injections of Candin® 0.3 ml until lesion resolves or up to 6 injections.
- interventionNames
- Biological: Candida albicans Skin Test Antigen
Primary outcomes (1)
- measure
- Number of Participants With Complete Resolution of Primary Injected Wart
- timeFrame
- Monthly evaluations during injection visit for up to 5 months, the follow up visits at 1 and 4 months after last dose for a total of approximately 9 months
Secondary outcomes (1)
- measure
- Number of Participants With Complete Resolution of the Primary Injected Wart by Number of Injection Visits
- timeFrame
- Monthly evaluations during injection visit for up to 5 months, the follow up visits at 1 and 4 months after last dose for a total of approximately 9 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Must have at least 3 and not more than 10 common warts not located on the palms or digits * Positive DTH response to Candin® required Exclusion Criteria: * No previous medical treatment for warts other than OTC * No immunocompromising medical conditions or medicines allowed * No preexisting inflammatory conditions at treatment site allowed
References
Publications (0)
Data not yet available
No reference posted for this study.